just $0.3 million in the same quarter last year. Revenues in the third quarter were $9.5 million vs. Xeris already has a growing income stream from Gvoke. The market for severe of these is huge and Xeris has stated that it would be interested in partnerships that will help to cover the expenses of bringing these drugs to market. The company has three other drugs in phase two studies and one in stage one. A final decision will be made in the first quarter of 2021 and the company should launch in Europe in the second half of the year. Last week Xeris received news that the European Union Committee for Medicinal Products recommends Gvoke for the treatment of severe hypoglycemia of people with Diabetes mellitus. The key is that the formulation is 'non-aqueous' and can be used for other drugs, as well. Previously the only product available required mixing chemicals before the injection could be done. The company’s lead product is the Gvoke HypoPen that allows an immediate injection for severe hypoglycemia, which is when diabetics have a sudden drop in blood sugar. Report is a specialty company that develops a ready-to-use injectable drug system. Xeris Pharmaceuticals ( XERS) - Get Xeris Biopharma Holdings, Inc. The balance sheet is very strong after the secondary offerings Xeris Pharma Has a Good Shot Sales are projected to grow to around $12 million in 2021 from $2 million to $3 million in 2020. NNDM is still in very early growth stages and has had some setbacks due to Covid-19. It has added shares in the offerings done by NNDM.

ARK is known for its bullish view of Tesla ( TSLA) - Get Tesla Inc Report and has been one of the top-performing funds in 2020. NNDM has been aggressively raising capital with several secondary offerings, but underlying support has remained quite strong in large part due to the ARK Autonomous Technology & Robotics exchange-traded fund ( ARKQ) - Get ARK Autonomous Technology & Robotics ETF Report, which held 3,884,929 shares as of Dec.

Marijuana micro cap stocks